What Is PDUFA? A Complete Guide for Biotech Investors

What Is PDUFA?

PDUFA stands for the Prescription Drug User Fee Act, a landmark U.S. law first enacted in 1992. Under PDUFA, pharmaceutical and biotech companies pay fees to the FDA when submitting drug applications. In return, the FDA commits to reviewing those applications within specific timeframes.

The most important outcome for investors is the PDUFA action date — the deadline by which the FDA must complete its review of a New Drug Application (NDA) or Biologics License Application (BLA).

Why PDUFA Dates Matter to Investors

PDUFA dates are the single most watched catalysts in biotech investing. Here's why:

• Binary outcome: The FDA will either approve the drug, issue a Complete Response Letter (CRL), or extend the review. This creates a binary event with significant price impact.
• Known in advance: PDUFA dates are publicly disclosed, typically 10-12 months before the action date.
• High volatility: Biotech stocks can move 50-200% on PDUFA outcomes, making them the highest-impact events in the sector.
• Asymmetric risk/reward: If you can identify undervalued companies with high approval probability, the risk/reward profile can be highly favorable.

How the FDA Review Timeline Works

When a company submits an NDA or BLA, the FDA follows a structured review process:

• Day 0: FDA receives the application
• Day 60: FDA files the application (or refuses to file)
• Filing date sets the PDUFA date: Standard review = 10 months from submission, Priority review = 6 months
• Advisory Committee (AdCom): The FDA may convene an advisory panel to vote on the drug — this typically happens 1-3 months before the PDUFA date
• PDUFA action date: FDA announces its decision — Approval, CRL, or 3-month extension

Types of FDA Review

• Standard Review (10 months): For drugs that offer similar benefits to existing treatments
• Priority Review (6 months): For drugs that offer significant improvements over existing treatments
• Breakthrough Therapy: Expedited development and review for serious conditions
• Accelerated Approval: Based on surrogate endpoints for serious conditions with unmet need

How to Track PDUFA Dates

Staying on top of PDUFA dates requires monitoring multiple sources:

• FDA official calendar and press releases
• SEC filings (8-K disclosures when companies receive PDUFA dates)
• ClinicalTrials.gov (for trial completion timelines that precede submissions)
• Company investor presentations and earnings calls

BioSniper's event calendar aggregates all of these sources into a single view, updated hourly. You can browse all upcoming PDUFA dates at biosniper.co/calendar/pdufa.

Key Factors That Predict PDUFA Outcomes

When evaluating a PDUFA catalyst, experienced analysts consider:

• Phase 3 trial results: Did the drug meet its primary endpoint? What were the safety signals?
• AdCom vote: If an advisory committee voted, what was the margin? A strong positive vote (e.g., 12-1) is highly predictive of approval.
• Complete Response Letter history: Has the drug received a CRL before? CRL resubmissions have different dynamics.
• FDA precedent: Has the FDA approved drugs with similar mechanisms or for the same indication?
• Manufacturing readiness: FDA can delay approval over manufacturing concerns.

Common Mistakes to Avoid

• Ignoring the CRL scenario: Even drugs with strong Phase 3 data can receive CRLs for manufacturing or labeling issues
• Not checking for AdCom: An unexpected AdCom meeting can inject volatility before the PDUFA date
• Assuming the date is fixed: The FDA can extend the review by 3 months if the company submits a major amendment
• Concentrating positions: Given the binary nature of PDUFA events, position sizing and risk management are critical

Summary

PDUFA dates are the most important dates on any biotech investor's calendar. Understanding the FDA review process, knowing when key dates are approaching, and analyzing the probability of approval are essential skills for biotech investing.

Track all upcoming PDUFA dates in real time with BioSniper's free biotech event calendar.